Results 11 to 20 of about 43,360 (234)

Relationship between NAFLD and coronary artery disease: A Mendelian randomization study

Hepatology, EarlyView., 2022
Abstract Background and Aims There is an ongoing debate on whether NAFLD is an active contributor or an innocent bystander in the pathogenesis of coronary artery disease (CAD). The aim of the present study was to assess the causal relationship between NAFLD and CAD.
Zhewen Ren, Pomme I. H. G. Simons, Anke Wesselius, Coen D. A. Stehouwer, Martijn C. G. J. Brouwers   +4 more
wiley   +1 more source

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism

Hepatology, EarlyView., 2022
Hepatic APOF transcript levels correlate inversely with plasma TG and hepatic steatosis in humans. ApoF expression in mice promotes VLDL‐TG production and lipoprotein remnant clearance in mice. Abstract Background NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD,
Audrey Deprince, Nathalie Hennuyer, Sander Kooijman, Amanda C. M. Pronk, Eric Baugé, Viktor Lienard, An Verrijken, Eveline Dirinck, Luisa Vonghia, Eloïse Woitrain, Niels J. Kloosterhuis, Eléonore Marez, Pauline Jacquemain, Justina C. Wolters, Fanny Lalloyer, Delphine Eberlé, Sandrine Quemener, Emmanuelle Vallez, Anne Tailleux, Mostafa Kouach, Jean‐Francois Goossens, Violeta Raverdy, Bruno Derudas, Jan Albert Kuivenhoven, Mikaël Croyal, Bart van de Sluis, Sven Francque, François Pattou, Patrick C. N. Rensen, Bart Staels, Joel T. Haas   +30 more
wiley   +1 more source

Loss of hepatic SMLR1 causes hepatosteatosis and protects against atherosclerosis due to decreased hepatic VLDL secretion

Hepatology, EarlyView., 2022
The role of SMLR1 in lipid metabolism (high fat + cholesterol diet in mice) Abstract Background and Aims The assembly and secretion of VLDL from the liver, a pathway that affects hepatic and plasma lipids, remains incompletely understood. We set out to identify players in the VLDL biogenesis pathway by identifying genes that are co‐expressed with the ...
Willemien van Zwol, Antoine Rimbert, Justina C. Wolters, Marieke Smit, Vincent W. Bloks, Niels J. Kloosterhuis, Nicolette C. A. Huijkman, Mirjam H. Koster, Umesh Tharehalli, Simon M. de Neck, Colin Bournez, Marceline M. Fuh, Jeroen Kuipers, Sujith Rajan, Alain de Bruin, Henry N. Ginsberg, Gerard J. P. van Westen, M. Mahmood Hussain, Ludger Scheja, Joerg Heeren, Philip Zimmerman, Bart van de Sluis, Jan Albert Kuivenhoven   +22 more
wiley   +1 more source

Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome

Journal of Lipid Research, 2012
We examined the effects of fenofibrate and atorvastatin on very low density lipoprotein (VLDL) apolipoprotein (apo)E metabolism in the metabolic syndrome (MetS). We studied 11 MetS men in a randomized, double-blind, crossover trial.
Esther M.M. Ooi, Theodore W.K. Ng, Gerald F. Watts, Dick C. Chan, P. Hugh R. Barrett   +4 more
doaj   +1 more source

Resistance of a very low density lipoprotein subpopulation from familial dysbetalipoproteinemia to in vitro lipolytic conversion to the low density lipoprotein density fraction.

Journal of Lipid Research, 1983
In vitro lipolysis of very low density lipoprotein (VLDL) from normolipidemic and familial dysbetalipoproteinemic plasma by purified bovine milk lipoprotein lipase was studied using the combined single vertical spin and vertical autoprofile method of ...
B H Chung, J P Segrest
doaj   +1 more source

To Investigate the Effect of Dyslipidemia and Metabolic Function in Coronary Heart Disease with Type 2 Diabetes Mellitus—In the Tertiary Care Center. A Study Protocol

Journal of Pharmacy and Bioallied Sciences
Introduction: Type 2 DM is the most common type of diabetes and it is characterized by a combination of insulin resistance and relative insulin shortage caused by pancreatic beta cell failure.
Akansha Singh, Ranjit S. Ambad, Roshan Kumar Jha, Rakesh Kumar Jha   +3 more
doaj   +1 more source

Moderate dyslipoproteinemia induced inflammation and remodeling HDL and VLDL particles in post-renal transplant patients

Current Issues in Pharmacy and Medical Sciences, 2017
The aim of this paper was to examine whether moderate dyslipoproteinemia can cause an increase of hsCRP and LPO levels in Tx patients who had received immunosuppressive therapy and were without acute inflammatory diseases. Herein, the lipid levels, hsCRP,
Kimak Elzbieta, Baranowicz-Gaszczyk Iwona, Bialopiotrowicz Tomasz   +2 more
doaj   +1 more source

VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: involvement of the VLDL receptor

Journal of Lipid Research, 1999
The potential role of the very low density lipoprotein (VLDL) receptor in mediating VLDL-induced plasminogen activator inhibitor-1 (PAI-1) expression was studied in vitro.
Lennart Nilsson, Mats Gåfvels, Leena Musakka, Katharina Ensler, Dudley K. Strickland, Bo Angelin, Anders Hamsten, Per Eriksson   +7 more
doaj   +1 more source

Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism

Journal of Lipid Research, 2008
Cholesteryl ester transfer protein (CETP) inhibition leads to changes in lipoprotein metabolism. We studied the effect of the CETP inhibitor torcetrapib on VLDL apolipoprotein E (apoE) metabolism.
John S. Millar, Margaret E. Brousseau, Margaret R. Diffenderfer, P. Hugh R. Barrett, Francine K. Welty, Jeffrey S. Cohn, Aisha Wilson, Megan L. Wolfe, Chorthip Nartsupha, Peter M. Schaefer, Andres G. Digenio, James P. Mancuso, Gregory G. Dolnikowski, Ernst J. Schaefer, Daniel J. Rader   +14 more
doaj   +1 more source

Plasma clearance and biodistribution of oxidatively modified 99mTc-ß-VLDL in rabbits

Brazilian Journal of Medical and Biological Research, 1997
The biodistribution and removal from plasma (measured as fractional clearance rate, FCR, per hour) of native and oxidatively modified 99mtechnetium-labeled ß-very low density lipoprotein (99mTc-ß-VLDL) were investigated in hypercholesterolemic (HC) and ...
E.L. Silva, J.C. Meneghetti, I.J.C Coelho, D.S.P Abdalla   +3 more
doaj   +1 more source